Labeling.cslbehring.com

Labeling.cslbehring.com has Server used 12.3.33.225 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first Unknown and hosted in United States, server ping response time 33 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Labeling keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Labeling
2 Labeling theory
3 Labeling machine
4 Labeling definition
5 Labeling theory criminology
6 Labeling a microscope
7 Labeling theory definition
8 Labeling theory sociology
9 Labeling or labelling

Hosting Provider

Website: Labeling.cslbehring.com
Hostname: testns.cslbehring.de
Country:
Latitude: 37.750999450684
Longitude: -97.821998596191
Area Code: 0
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

   Blueskyvineyard.com (45 seconds ago)

   Senlcy.com (3 seconds ago)

   Shoppartridgecreek.com (4 seconds ago)

   Freon-ac.com (11 seconds ago)

   Beelyrics.com (3 seconds ago)

   Guardianangelsraffle.com (8 seconds ago)

   Fatmatures.net (36 seconds ago)

   Vinobella.com (2 seconds ago)

   Trackerservicesllc.com (15 seconds ago)

   Rblys.com (58 seconds ago)

   Bcdorlando.com (11 seconds ago)

   Bombay-tools.com (19 seconds ago)

   Apnpr.com (4 seconds ago)

   I340b.com (3 seconds ago)

   Cheapest-20mg-tadalafil.com (5 seconds ago)

   Jubileebk.com (9 seconds ago)

   Zillow.com (7 seconds ago)

   Onenationoneflag.com (17 seconds ago)

   Versitec.org (6 seconds ago)

   Parkwareham.com (52 seconds ago)

Results For Websites Listing

Found 61 Websites with content related to this domain, It is result after search with search engine

Privigen Coding Information - labeling.cslbehring.com

Your single source for Ig solutions Call us now for reimbursement support Privigen reimbursement support is available free of charge through IgIQ, See full prescribing information for complete boxed warning. Privigen

https://labeling.cslbehring.com/PRODUCT-DOCUMENT/US/Privigen/EN/Privigen-Coding-Guide.pdf

CSL Behring CONTRAINDICATIONS Albumin (Human) USP, 25%

CSL Behring Albumin (Human) USP, 25% Albuminar®-25] only DESCRIPTION Albumin (Human) 25%, Albuminar®-25 is a sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled

https://labeling.cslbehring.com/PI/US/Albuminar25/EN/Albuminar25-Prescribing-Information.pdf

Corporate Responsibility - cslbehring.com

CSL Behring is a global biotech company leading the way to deliver innovative therapies for rare and serious diseases.

https://www.cslbehring.com/our-company/corporate-responsibility

Humate-P for von Willebrand Disease

Learn about Humate-P for von Willebrand Disease. This document is provided in Adobe ® Reader ® format (PDF). In order to view PDF documents, you must have the Adobe ® Reader ® software installed on your computer. If you do not have the Acrobat Reader, download it from the Adobe Web site.

https://www.humate-p.com/Professional/Prescribing-Information.aspx

IDELVION® Newly Approved 3500 IU Vial to Provide

KING OF PRUSSIA, Pa. – 31 May 2018 – Global biotherapeutics leader CSL Behring today announced that the US Food and Drug Administration (FDA) has approved a 3500 IU (international unit) vial size for IDELVION ® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP)], its novel, long-acting recombinant albumin fusion protein for treating hemophilia B.

https://www.cslbehring.com/newsroom/2018/20180531-fda-approves-idelvion-3500iu-vial

Clotting Factors - Medical Clinical Policy Bulletins | Aetna

For precertification of clotting factors, call Aetna's National Medical Excellence Program at (877) 212-8811. Note: This policy applies only to clotting factor products available through pharmaceutical suppliers. Cryoprecipitated clotting factors are available only through blood banks and have slightly different indications. Background

http://www.aetna.com/cpb/medical/data/100_199/0131.html

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use IDELVION® safely and effectively. See full prescribing information for

https://www.fda.gov/media/96526/download

FDA Approves Hizentra for CIDP Treatment | MDedge Neurology

CSL Behring recently announced that the US Food and Drug Administration (FDA) has approved Hizentra (immune globulin subcutaneous [human] 20% liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

https://www.mdedge.com/neurology/clinical-edge/summary/fda-actions/fda-approves-hizentra-cidp-treatment

FDA Green Lights CSL Behring’s Idelvion for Hemophilia B

In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL Behring’s long-acting recombinant albumin fusion protein, delivers on the company’s promise to develop and

https://www.pharmalive.com/fda-green-lights-csl-behrings-idelvion-for-hemophilia-b/

FDA Approves Hizentra for CIDP Treatment | Clinical

CSL Behring recently announced that the US Food and Drug Administration (FDA) has approved Hizentra (immune globulin subcutaneous [human] 20% liquid) as the first and only subcutaneous immunoglobulin (SCIg) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.

https://www.mdedge.com/clinicalneurologynews/clinical-edge/summary/fda-actions/fda-approves-hizentra-cidp-treatment

Recently Analyzed Sites